Skip to main content
×
×
Home

Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T

  • Reggie Taylor (a1), Elizabeth A. Osuch (a2), Betsy Schaefer (a3), Nagalingam Rajakumar (a4), Richard W. J. Neufeld (a5), Jean Théberge (a6) and Peter C. Williamson (a7)...
Abstract
Background

Examining neurometabolic abnormalities in critical brain areas in schizophrenia and major depressive disorder (MDD) may help guide future pharmacological interventions including glutamate-modulating treatments.

Aims

To measure metabolite concentrations within the anterior cingulate cortex (ACC) and thalamus of people with schizophrenia and people with MDD.

Methods

Spectra were acquired from 16 volunteers with schizophrenia, 17 with MDD and 18 healthy controls using magnetic resonance spectroscopy on a 7 Tesla scanner.

Results

In the thalamus, there were lower glycine concentrations in the schizophrenia group relative to control (P=0.017) and MDD groups (P=0.012), and higher glutamine concentrations relative to healthy controls (P=0.009). In the thalamus and the ACC, the MDD group had lower myo-inositol concentrations than the control (P=0.014, P=0.009, respectively) and schizophrenia (P=0.004, P=0.002, respectively) groups.

Conclusion

These results support the glutamatergic theory of schizophrenia and indicate a potential glycine deficiency in the thalamus. In addition, reduced myo-inositol concentrations in MDD suggest its involvement in the disorder.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T
      Available formats
      ×
Copyright
This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) license.
Corresponding author
Correspondence: Reggie Taylor, 268 Grosvenor St., Room E5-118, London, Ontario, Canada N6A 4V2. Email: rtaylor@lawsonimaging.ca
Footnotes
Hide All

Declaration of interest

None.

Footnotes
References
Hide All
1 Poels, EMP, Kegeles, LS, Kantrowitz, JT, Slifstein, M, Javitt, DC, Lieberman, JA, et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry 2014; 19: 20–9.
2 Coyle, JT, Tsai, G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology 2004; 174: 32–8.
3 Gilbert-Rahola, J, Villena-Rodriguez, A. Glutamatergic drugs for schizophrenia treatment. Actas espaholas Psiquiatr 2014; 42: 234–41.
4 Javitt, DC, Zukin, SR, Heresco-Levy, U, Umbricht, D. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull 2012; 38: 958–66.
5 Théberge, J, Bartha, R, Drost, DJ, Menon, RS, Malla, A, Takhar, J, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 2002; 159: 1944–6.
6 Marsman, A, Van Den Heuvel, MP, Klomp, DWJ, Kahn, RS, Luijten, PR, Hulshoff Pol, HE. Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophr Bull 2013; 39: 120–9.
7 Harvey, RJ, Yee, BK. Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov 2013; 12: 866–85.
8 Williamson, P. Are anticorrelated networks in the brain relevant to schizophrenia? Schizophr Bull 2007; 33: 9941003.
9 Théberge, J, Al-Semaan, Y, Williamson, PC, Menon, RS, Neufeld, RWJ, Rajakumar, N, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003; 160: 2231–3.
10 Taylor, R, Neufeld, RWJ, Schaefer, B, Densmore, M, Rajakumar, N, Osuch, EA, et al. Functional magnetic resonance spectroscopy of glutamate in schizophrenia and major depressive disorder: anterior cingulate activity during a color-word Stroop task. npj Schizophrenia 2015; 1: 15028 (http://www.nature.com/articles/npjschz201528).
11 Boksman, K, Théberge, J, Williamson, P, Drost, DJ, Malla, A, Densmore, M, et al. A 4.0-T fMRI study of brain connectivity during word fluency in first-episode schizophrenia. Schizophr Res 2005; 75: 247–63.
12 Yildiz-Yesiloglu, A, Ankerst, DP. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res Neuroimaging 2006; 147: 125.
13 Chen, LP, Dai, HY, Dai, ZZ, Xu, CT, Wu, RH. Anterior cingulate cortex and cerebellar hemisphere neurometabolite changes in depression treatment: a 1H magnetic resonance spectroscopy study. Psychiatry Clin Neurosci 2014; 68: 357–64.
14 Coupland, NJ, Ogilvie, CJ, Hegadoren, KM, Seres, P, Hanstock, CC, Allen, PS. Decreased prefrontal myo-inositol in major depressive disorder. Biol Psychiatry 2005; 57: 1526–34.
15 First, M, Spitzer, R, Gibbon, M, Williams, J. Structured Clinical Interview (SCID) for DSM-IV Axis 1 Disorders. American Psychiatric Press, 1997.
16 Andreasen, NC. Scale for the Assessment of Positive Symptoms (SAPS). The University of Iowa, 1984.
17 Andreasen NC. Scale for the Assessment of Negative Symptoms (SAPS). The University of Iowa, 1984.
18 Montgomery, SA, Asberg, M. Scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9.
19 Young, RC, Biggs, JT, Ziegler, VE, Meyer, DA. A rating scale for mania: reliability, validity and sensitivity a rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 2011; 133: 429–35.
20 Hamilton, M. Rating depressive patients. J Clin Psychiatry 1980; 41(12 pt 2): 21–4.
21 Aoyama, N, Théberge, J, Drost, DJ, Manchanda, R, Northcott, S, Neufeld, RWJ, et al. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br J Psychiatry 2011; 198: 448–56.
22 Gilbert, KM, Curtis, AT, Gati, JS, Klassen, LM, Menon, RS. A radiofrequency coil to facilitate B1+ shimming and parallel imaging acceleration in three dimensions at 7 T. NMR Biomed 2011; 24: 815–23.
23 Curtis, AT, Gilbert, KM, Klassen, LM, Gati, JS, Menon, RS. Slice-by-slice B1+ shimming at 7 T. Magn Reson Med 2012; 68: 1109–16.
24 Klassen, LM, Menon, RS. Robust automated shimming technique using arbitrary mapping acquisition parameters (RASTAMAP). Magn Reson Med 2004; 51: 881–7.
25 Tkac, I, Gruetter, R. Methodology of 1 H NMR spectroscopy of the human brain at very high magnetic fields. Appl Magn Reson 2005; 29: 139–57.
26 Penner, J, Bartha, R. Semi-LASER 1H MR spectroscopy at 7 Tesla in human braIn: metabolite quantification incorporating subject-specific macromolecule removal. Magn Reson Med 2014; 74: 412.
27 Brown, MA. Time-domain combination of MR spectroscopy data acquired using phased-array coils. Magn Reson Med 2004; 52: 1207–13.
28 Bartha, R, Drost, DJ, Menon, RS, Williamson, PC. Spectroscopic lineshape correction by QUECC: combined QUALITY deconvolution and eddy current correction. Magn Reson Med 2000; 44: 641–5.
29 Bartha, R, Drost, DJ, Williamson, PC. Factors affecting the quantification of short echo in-vivo 1 H MR spectra: prior knowledge, peak elimination, and filtering. NMR Biomed 1999; 12: 205–16.
30 Marascuilo, LA, Levin, JR. Multivariate Statistics in the Social Sciences. Brooks/Cole, 1983.
31 Soher, BJ, Young, K, Bernstein, A, Aygula, Z, Maudsley, AA. GAVA: spectral simulation for in vivo MRS applications. J Magn Reson 2007; 185: 291–9.
32 Krawczyk, H, Gradowska, W. Characterisation of the 1H and 13C NMR spectra of N-acetylaspartylglutamate and its detection in urine from patients with Canavan disease. J Pharm Biomed Anal 2003; 31: 455–63.
33 Govindaraju, V, Young, K, Maudsley, AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000; 13: 129–53.
34 Mangia, S, Tkác, I, Gruetter, R, Van de Moortele, P-F, Maraviglia, B, Uğurbil, K. Sustained neuronal activation raises oxidative metabolism to a new steady-state level: evidence from 1H NMR spectroscopy in the human visual cortex. J Cereb Blood Flow Metab 2007; 27: 1055–63.
35 Mark, LP, Prost, RW, Ulmer, JL, Smith, MM, Daniels, DL, Strottmann, JM, et al. Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging. Am J Neuroradiol 2001; 22: 1813–24.
36 Kosenko, E, Llansola, M, Montoliu, C, Monfort, P, Rodrigo, R, Hernandez-Viadel, M, et al. Glutamine synthetase activity and glutamine content in braIn: modulation by NMDA receptors and nitric oxide. Neurochem Int 2003; 43: 493–9.
37 Yamamori, H, Hashimoto, R, Fujita, Y, Numata, S, Yasuda, Y, Fujimoto, M, et al. Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment. Neurosci Lett 2014; 582: 93–8.
38 Hons, J, Vasatova, M, Cermakova, E, Doubek, P, Libiger, J. Different serine and glycine metabolism in patients with schizophrenia receiving clozapine. J Psychiatr Res 2012; 46: 811–8.
39 Lin, Y, Stephenson, MC, Xin, L, Napolitano, A, Morris, PG. Investigating the metabolic changes due to visual stimulation using functional proton magnetic resonance spectroscopy at 7 T. J Cereb Blood Flow Metab 2012; 32: 1484–95.
40 Kaufman, MJ, Prescot, AP, Ongur, D, Evins, AE, Barros, TL, Medeiros, CL, et al. Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study. Psychiatry Res – Neuroimaging 2009; 173: 143–9.
41 Umbricht, D, Alberati, D, Martin-Facklam, M, Borroni, E, Youssef, EA, Ostland, M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry 2014; 71: 637–46.
42 Strzelecki, D, Podgorski, M, Kaluzynska, O, Gawlik-Kotelnicka, O, Stefanczyk, L, Kotlicka-Antczak, M, et al. Supplementation of antipsychotic treatment with sarcosine – G1yT1 inhibitor – causes changes of glutamatergic 1NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia. Neurosci Lett 2015; 606: 712.
43 Fisher, SK, Novak, JE, Agranoff, BW. Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J Neurochem 2002; 82: 736–54.
44 Barkai, A, Dunner, D, Gross, H, Mayo, P, Fieve, R. Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder. Biol Psychiatry 1978; 13: 6572.
45 Kofman, O, Belmaker, RH. Ziskind-Somerfeld Research Award 1993. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression. Biol Psychiatry 1993; 34: 839–52.
46 Mukai, T, Kishi, T, Matsuda, Y, Iwata, N. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol 2014; 29: 5563.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Open
  • ISSN: -
  • EISSN: 2056-4724
  • URL: /core/journals/bjpsych-open
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 5
Total number of PDF views: 33 *
Loading metrics...

Abstract views

Total abstract views: 117 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 19th July 2018. This data will be updated every 24 hours.

Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T

  • Reggie Taylor (a1), Elizabeth A. Osuch (a2), Betsy Schaefer (a3), Nagalingam Rajakumar (a4), Richard W. J. Neufeld (a5), Jean Théberge (a6) and Peter C. Williamson (a7)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *